BiotechTube

YHR1705 + YHR1706 + YHR1705+YHR1706

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dyslipidemia

Conditions

Dyslipidemia, Type 2 Diabetes Mellitus

Trial Timeline

Aug 7, 2017 → Sep 19, 2017

NCT ID
NCT03235362

About YHR1705 + YHR1706 + YHR1705+YHR1706

YHR1705 + YHR1706 + YHR1705+YHR1706 is a phase 1 stage product being developed by Yuhan for Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03235362. Target conditions include Dyslipidemia, Type 2 Diabetes Mellitus.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03235362Phase 1Completed

Competing Products

20 competing products in Dyslipidemia

See all competitors
ProductCompanyStageHype Score
LY3202328 + Placebo + Atorvastatin + SimvastatinEli LillyPhase 1
33
Pitavastatin + PravastatinEli LillyApproved
85
Rosuampin 10/5mg + Rosuampin 20/5mg + Amlodipine/Atorvastatin 5/20mgYuhanApproved
85
YH14755 + Metformin + RosuvastatinYuhanPhase 3
77
Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapyYuhanPre-clinical
23
Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDCYuhanPhase 1
33
MevalotinDaiichi SankyoPre-clinical
23
PravastatinDaiichi SankyoPre-clinical
23
LY3475766 - IV + LY3475766 - SC + Placebo - IV + Placebo - SCEli LillyPhase 1
33
LY3885125 + PlaceboEli LillyPhase 1
33
LY3561774 + PlaceboEli LillyPhase 1
33
LY2484595 + Atorvastatin + Simvastatin + Rosuvastatin + Placebo for LY2484595 + Placebo for StatinsEli LillyPhase 2
52
LY3561774 + PlaceboEli LillyPhase 2
52
LY2484595 + Placebo + AtorvastatinEli LillyPhase 2
52
EvacetrapibEli LillyPhase 1
33
PPAR alpha + placeboEli LillyPhase 2
52
AZD0780 + Ezetimibe + Rosuvastatin + Bempedoic Acid + PlaceboAstraZenecaPhase 1
33
ABT-335 + RosuvastatinAstraZenecaPhase 1
33
AZD6615 + PlaceboAstraZenecaPhase 1
33
AZD0780 + AZD0780 + AZD0780 + Placebo + Placebo + Placebo + RosuvastatinAstraZenecaPhase 1
33

Other Products from Yuhan

generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85